Recent Conferences
November 24, 2008
Medicare Delivery System Reform
October 2, 2008
Specialty Pharmaceuticals: Policy Solutions for Encouraging Access and Affordability
July 16, 2008
Managing Specialty Pharmaceuticals
June 4, 2008
"Road Testing" Electronic Medical Records
April 30, 2008
Innovation Workgroup
April 10, 2008
Payment and Delivery System Reform
November 29, 2007
Comparative Effectiveness Congressional Briefing
November 27, 2007
Overview of Cost Management Strategies
October 24, 2007
Coverage With Evidence Development
October 2, 2007
Value-Based Payment for Medical Technologies
September 18, 2007
Personalized Medicine Conference
July 25, 2007
Comparative Effectiveness: Stakeholder Perspectives
April 11, 2007
Post Marketing Surveillance
November 30, 2006
Comparative Effectiveness Forum
October 12, 2006
Coverage Policy in an Era of Personalized Medicine
July 13, 2006
Pharmaceutical Benefit Management
May 1, 2006
Methodology Standards
April 4, 2006
Technology Assessment
October 3, 2005
Promoting Appropriate Utilization
April 1, 2005
Evidence-Based Health Care System
July 16, 2004
Correcting Underuse in Health Care
April 11, 2007
Developing an Effective Long Term Strategy for Post Marketing Surveillance of Medical Products
This Forum on Developing an Effective Long-Term Strategy for Post-Marketing Surveillance of Medical Products brought together leaders from industry, government, the public (consumer advocates), and academia to examine in practical terms how to establish a more effective post-marketing capacity in the U.S.
Presentations:
The Future of Drug Safety: Recommendations of the IOM
Robert B. Giffin, Ph.D., Director, Drug Discovery, Development and Translation Forum, Institute of Medicine
Strategies for Establishing An Effective Long Term Post Marketing Surveillance Capacity
Scott Gottlieb, M.D., Resident Fellow, American Enterprise Institute
Building Blocks for a Post Market Surveillance System
Janet Woodcock, M.D., Deputy Commissioner and Chief Medical Officer, FDA, Center for Drug Evaluation and Research
Building Blocks for a Post Marketing Surveillance System
K. Arnold Chan, M.D., Sc.D., FISPE, Senior Scientist, i3 Drug Safety
Enhancing Post-Marketing Surveillance
Adrian Thomas, Chief Safety Officer, Johnson & Johnson
Background Materials:
- Raymond L. Woosley's Testimony on "The Adequacy of FDA to Assure the Safety of the Drug Supply - Part II"
- Mark McClellan's Testimony on "Fundamental Improvements in Drug Safety for the 21st Century: Time for a Systematic, Electronic Infrastructure"
- Bruce M. Psaty and Sheila P. Burke: "Protecting the Health of the Public-Institute of Medicine Recommendations on Drug Safety."
- Scott Gottlieb: "Opening Pandora's Pillbox: Using Modern Information Tools to Improve Drug Safety."
- Brian L. Strom: "How the US Drug Safety System Should Be Changed."
